Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Beijing appears to be extending an olive branch to the previously under-fire drug maker as it tries to shore up private ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase ...

This can be found among the Granolas, a group of 11 European multinationals, selected by US bank Goldman Sachs, which is made ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: $7.0 billion (+18%) Comments: Oncology sales were $22.4 billion, up 21%.

Recent health news highlights controversial language restrictions within the FDA, legal actions against vape distributors in ...

The stable outlook reflects Moody's expectation that AstraZeneca will maintain solid organic growth in revenues and EBITDA and continue to execute successfully on its new product pipeline. The outlook ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax wit ...